CIBC Asset Management
IPXL

CIBC Asset Management’s Impax Laboratories, Inc. IPXL Stock Holding History

CIBC Asset Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-7,633
Closed -$202K – 971
2014
Q1 		$202K Buy
+7,633
New +$191K ﹤0.01% 944

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CIBC Asset Management's IPXL Position: Q2 2014 in Review

CIBC Asset Management sold out of Impax Laboratories, Inc. (IPXL) in Q2 2014, closing a stake of 7,633 shares — an estimated $202K sold.

CIBC Asset Management first reported a position in IPXL in Q1 2014 and held it in 1 quarter. The position peaked at $202K in Q1 2014. 185 funds tracked by Wall St. Rank hold IPXL as of Q2 2014.

  • CIBC Asset Management reported no remaining Impax Laboratories, Inc. position as of Q2 2014 after selling out during the quarter.
  • CIBC Asset Management sold 7,633 Impax Laboratories, Inc. shares in Q2 2014, an estimated $202K.
  • CIBC Asset Management first reported a position in Impax Laboratories, Inc. in Q1 2014 and held it in 1 quarter.
  • CIBC Asset Management's Impax Laboratories, Inc. position peaked at $202K in Q1 2014.
  • 185 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2014.

Based on CIBC Asset Management's 13F filing for Q2 2014, filed 1 Aug 2014.